100+ Biomarkers | 199 € / YeAR
Start Membership
His protocol is fascinating. His methodology is what actually matters and it’s the one thing you can replicate without a billionaire’s budget.
Every few months, another wave of content arrives about Bryan Johnson. His morning routine. His 111-pill supplement stack. His “don’t die” manifesto. His meal schedules, his plasma transfusions, his 10pm bedtime.
Johnson is not interesting because of what he does. He is interesting because of how he decided to do it. He runs 100+ biomarkers every quarter, publishes the data publicly, and adjusts his protocol based on what the numbers say. He never starts from a conclusion. He starts from measurement.
The goal isn’t to replicate his results. The goal is to understand why he has data and most men don’t, and to fix that.
This is not an endorsement of Johnson’s protocol. It is a breakdown of what his published biomarker data actually shows, and what it means in the context of standard German preventive care.
Johnson publishes his health data at blueprint.bryanjohnson.com. Rather than summarising his supplement list, here are the markers he monitors most obsessively, and what his reported values reveal about the gap between population “normal” and genuine optimisation.
That principle: test first; intervene second; re-test always, is the one thing about the Blueprint protocol that every man can actually use. And in Germany, where the statutory health system tests five markers every three years and calls it preventive care, it is also the one thing almost no one is doing.
Everyone is copying his conclusions. He built them on a principle you can replicate for €199.
Most coverage of Bryan Johnson treats him as a protocol to be copied or dismissed. That framing misses everything. His protocol is the output. His methodology is the input. And his methodology has one irreducible principle: you never intervene without measuring first. You never continue an intervention without measuring again.
This is not so much an insight only select number of billionaires are privy too. It is basic experimental design. The same approach any scientist would apply. What makes Johnson unusual is that he applies it with obsessive consistency to his own body, and he publishes the data so others can learn from it.
The people who dismiss him as extreme are missing a useful signal. The people who copy his 111-pill stack without any baseline testing may be doing something even considerably worse: they’re skipping the one step that makes the whole approach meaningful.
Johnson doesn’t know if something is working because he feels better. He knows because his hs-CRP moved, his ApoB shifted, his fasting insulin changed. You cannot track what you haven’t measured.
A single data point is noise. Two data points are a direction. Three are a trend.
Johnson's published data shows what is achievable when you test comprehensively, interpret against optimal ranges, and adjust based on what changes. His hs-CRP below 0.2 is not a genetic gift. It is the result of measuring it, identifying it was elevated, and systematically addressing the drivers.
His ApoB in the lowest percentile did not happen by accident. He measured it, found it too high for his goals, changed his dietary approach, and tested again. That loop — measure, act, re-measure, is available to anyone. The only barrier is having the data to start.
You do not need $2M or 111 supplements. You need a comprehensive baseline, someone qualified to interpret it, and a clear picture of where your specific gaps are. That is the one thing in his protocol that is universally applicable and it is the one thing most men in Germany have never done.
Bryan Johnson's protocol is built on comprehensive measurement. The German statutory health system's preventive check-up, the Check-up 35, covers five standard blood markers every three years and is presented as adequate preventive care. The gap between these two approaches is not a matter of budget. It is a matter of what you decide to look for.
Total cholesterol, LDL, HDL, triglycerides, fasting glucose. Five values, available once every three years from age 35. No thyroid, no iron, no inflammation markers, no hormones, no insulin. This is the statutory preventive blood testing entitlement for every GKV member in Germany.
The average Hausarzt appointment in Germany lasts roughly 7–8 minutes. In that window: history, examination, prescription, and discussion. There is functionally no time for a GP to design a comprehensive preventive panel, explain results in depth, and discuss what optimal ranges actually mean for a 35-year-old who feels fine but wants to understand more.
According to the Robert Koch Institut's DEGS1 study, more than half of German adults have vitamin D levels below the threshold most researchers consider optimal for immune function and bone health. This is published RKI data. Vitamin D is not tested by the Check-up 35 and not routinely ordered by GPs without specific symptoms.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition worldwide, affecting an estimated third of adults. Most have no symptoms and no awareness of it. ALT and AST, the liver enzymes that show early stress, are not part of the Check-up 35 and not in the großes Blutbild. They are available on request, often as out-of-pocket costs.
Run the same markers Bryan Johnson tracks quarterly. Accredited German labs. Clinician-reviewed action plan. €199 / year.
It does not prove that his specific protocol is right for you. It does not prove that his supplement stack is optimal, or that his sleep schedule is necessary, or that his extreme caloric restriction is worth replicating.
What it proves is considerably more useful: the markers that track long-term health outcomes are measurable, they are not exotic, and most people have never seen their own numbers.
His hs-CRP below 0.2 mg/L is not genetic luck. It is a measurable outcome that tracks directly with his sleep consistency, dietary pattern, exercise volume, and absence of visceral fat. It is a feedback signal.
The number tells him, and shows anyone reading his data, that the interventions are working. Or when they are not.
His ApoB at 55 mg/dL is not a side effect of other habits. It is a directly managed target.
He knows what his ApoB is because he tests it regularly. He knows whether it is moving in the right direction because he tracks the trend over time.
Most men in Germany have never seen their ApoB at all, the marker that the European Society of Cardiology now names as the primary cardiovascular risk indicator.
The gap is not money. A deep blood panel is not expensive.
Aniva's annual membership 100+ biomarkers, tested at a certified German lab, results interpreted against optimal ranges with a clinician-reviewed action plan: costs €199 per year.
That is roughly the cost of one extended private GP visit. The gap is information access.
Bryan Johnson is spending $2,000,000 to make a point. The point is: data about your own biology is the most valuable health investment you can make. He has a lot of money and is making it very loudly. The same principle applies at €199.
1. Bryan Johnson Blueprint — publicly published biomarker data. blueprint.bryanjohnson.com
2. European Society of Cardiology (ESC) Guidelines on Cardiovascular Disease Prevention, 2021. ApoB recommended as primary lipid risk marker.
3. Gemeinsamer Bundesausschuss (G-BA). Gesundheitsuntersuchung Check-up 35. Richtlinie über die Früherkennungsuntersuchungen, 2023.
4. Kraft JR. Detection of diabetes mellitus in situ (occult diabetes). Lab Med. 1975. Evidence for fasting insulin as early metabolic marker.
5. Kaaks R, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk. J Natl Cancer Inst. 2000.
6. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008.
7. Ballantyne CM, et al. Usefulness of apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol to evaluate cardiovascular disease risk. Am J Cardiol. 2008.
Every intervention Bryan Johnson makes is preceded by a test and followed by another. You don’t need $2M to apply the same principle. You need 100+ biomarkers, a certified German lab, and results that tell you where you actually stand. Not where you might be.
Complements your GP — does not replace them · EU data privacy · No subscription traps